CO6602117A2 - Derivados de aril triazol heteroaromáticos como inhibidores de enzima pde10a - Google Patents
Derivados de aril triazol heteroaromáticos como inhibidores de enzima pde10aInfo
- Publication number
- CO6602117A2 CO6602117A2 CO12101114A CO12101114A CO6602117A2 CO 6602117 A2 CO6602117 A2 CO 6602117A2 CO 12101114 A CO12101114 A CO 12101114A CO 12101114 A CO12101114 A CO 12101114A CO 6602117 A2 CO6602117 A2 CO 6602117A2
- Authority
- CO
- Colombia
- Prior art keywords
- present
- provides
- subject
- compound
- formula
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4196—1,2,4-Triazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Neurology (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Addiction (AREA)
- Psychiatry (AREA)
- Psychology (AREA)
- Epidemiology (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
La presente invención se dirige a compuestos, que son inhibidores de la enzima PDE1OA. La invención proporciona una composición farmacéutica que comprende una cantidad terapéuticamente efectiva de un compuesto de la invención y un portador farmacéuticamente aceptable. La presente invención también proporciona procesos para la preparación de los compuestos de la fórmula 1. La presente invención además proporciona un método de tratar un sujeto que padece de un trastorno neurodegenerativo que comprende la administración al sujeto de una cantidad terapéuticamente efectiva de un compuesto de la fórmula 1. La presente invención también proporciona un método para tratar a un sujeto que padece de adicción a las drogas que comprende la administración a un sujeto de una cantidad terapéuticamente efectiva de un compuesto de la fórmula 1. La presente invención además proporciona un método para tratar a un sujeto que padece de un trastorno psiquiátrico que comprende la administración al sujeto de una cantidad terapéuticamente efectiva de un compuesto de la fórmula 1.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DKPA200901340 | 2009-12-17 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CO6602117A2 true CO6602117A2 (es) | 2013-01-18 |
Family
ID=44246811
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CO12101114A CO6602117A2 (es) | 2009-12-17 | 2012-06-15 | Derivados de aril triazol heteroaromáticos como inhibidores de enzima pde10a |
Country Status (36)
| Country | Link |
|---|---|
| US (2) | US8501795B2 (es) |
| EP (1) | EP2513106B1 (es) |
| JP (1) | JP6035149B2 (es) |
| KR (1) | KR101779629B1 (es) |
| CN (1) | CN102753550B (es) |
| AR (1) | AR079496A1 (es) |
| AU (1) | AU2010333438B2 (es) |
| BR (1) | BR112012014486A2 (es) |
| CA (1) | CA2783728C (es) |
| CO (1) | CO6602117A2 (es) |
| CR (1) | CR20120318A (es) |
| CY (1) | CY1116361T1 (es) |
| DK (1) | DK2513106T3 (es) |
| DO (1) | DOP2012000169A (es) |
| EA (1) | EA021606B1 (es) |
| ES (1) | ES2442179T3 (es) |
| GE (1) | GEP20146201B (es) |
| GT (1) | GT201200193A (es) |
| HK (1) | HK1177745A1 (es) |
| HR (1) | HRP20131210T1 (es) |
| IL (1) | IL220328A (es) |
| MA (1) | MA33923B1 (es) |
| MX (1) | MX2012006715A (es) |
| MY (1) | MY156520A (es) |
| NZ (1) | NZ600365A (es) |
| PL (1) | PL2513106T3 (es) |
| PT (1) | PT2513106E (es) |
| RS (1) | RS53101B (es) |
| SG (1) | SG181672A1 (es) |
| SI (1) | SI2513106T1 (es) |
| SM (1) | SMT201400009B (es) |
| TN (1) | TN2012000278A1 (es) |
| TW (1) | TWI487705B (es) |
| UA (1) | UA107950C2 (es) |
| WO (1) | WO2011072697A1 (es) |
| ZA (1) | ZA201204420B (es) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI485151B (zh) | 2009-12-17 | 2015-05-21 | Lundbeck & Co As H | 作為ｐｄｅ１０ａ酵素抑制劑之雜芳香族苯基咪唑衍生物 |
| TWI487705B (zh) * | 2009-12-17 | 2015-06-11 | Lundbeck & Co As H | 作為ｐｄｅ１０ａ酵素抑制劑之雜芳香族芳基三唑衍生物 |
| TWI481607B (zh) * | 2009-12-17 | 2015-04-21 | Lundbeck & Co As H | 作為ｐｄｅ１０ａ酵素抑制劑的２－芳基咪唑衍生物 |
| CN103619841B (zh) | 2011-01-11 | 2017-03-29 | 桑诺维恩药品公司 | 杂芳基化合物及其使用方法 |
| JP2014510055A (ja) | 2011-02-18 | 2014-04-24 | アラーガン インコーポレイテッド | ホスホジエステラーゼ１０（ｐｄｅ１０ａ）阻害剤としての置換６，７−ジアルコキシ−３−イソキノリノール誘導体 |
| CA2846758C (en) * | 2011-09-19 | 2017-09-12 | F. Hoffmann-La Roche Ag | Triazolopyridine compounds as pde10a inhibitors |
| WO2013127817A1 (en) | 2012-02-27 | 2013-09-06 | H. Lundbeck A/S | Imidazole derivatives as pde10a enzyme inhibitors |
| WO2013178572A1 (en) | 2012-05-30 | 2013-12-05 | F. Hoffmann-La Roche Ag | Triazolo compounds as pde10 inhibitors |
| NZ702239A (en) | 2012-06-19 | 2017-01-27 | Sunovion Pharmaceuticals Inc | Heteroaryl compounds and methods of use thereof |
| WO2014071044A1 (en) | 2012-11-01 | 2014-05-08 | Allergan, Inc. | Substituted 6,7-dialkoxy-3-isoquinoline derivatives as inhibitors of phosphodiesterase 10 (pde10a) |
| EP2919781B1 (en) * | 2012-11-15 | 2017-06-28 | Merck Sharp & Dohme Corp. | Cyclobutyl benzimidazoles as pde10 inhibitors |
| CN105793256B (zh) * | 2013-11-28 | 2019-09-10 | 豪夫迈·罗氏有限公司 | 咪唑衍生物 |
| US9200016B2 (en) | 2013-12-05 | 2015-12-01 | Allergan, Inc. | Substituted 6, 7-dialkoxy-3-isoquinoline derivatives as inhibitors of phosphodiesterase 10 (PDE 10A) |
| CN114671874B (zh) * | 2021-08-30 | 2024-02-02 | 济南爱思医药科技有限公司 | 一种具有抗肿瘤活性的茶碱乙酸衍生物及其制备方法与应用 |
| WO2023064458A1 (en) * | 2021-10-13 | 2023-04-20 | Yale University | Selective jak2 inhibitors and methods of use |
Family Cites Families (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1462521A (en) | 1974-02-11 | 1977-01-26 | Wyeth John & Brother Ltd | Triazole derivatives |
| GB8307865D0 (en) | 1983-03-22 | 1983-04-27 | Fujisawa Pharmaceutical Co | Benzimidazole derivatives |
| US5571775A (en) | 1994-07-11 | 1996-11-05 | Dowelanco | N-aryl[1,2,4]triazolo[1,5-a]pyridine-2-sulfonamide herbicides |
| US6699853B2 (en) | 1997-06-16 | 2004-03-02 | Hoechst Schering Agrevo Gmbh | 4-haloalkyl-3-heterocyclylpyridines, 4-haloalkyl-5-heterocyclyl-pyrimidines and 4-trifluoromethyl-3-oxadiazolylpyridines, processes for their preparation, compositions comprising them, and their use as pesticides |
| SE9802937D0 (sv) | 1998-09-01 | 1998-09-01 | Astra Pharma Prod | Novel compounds |
| US20030032579A1 (en) | 2001-04-20 | 2003-02-13 | Pfizer Inc. | Therapeutic use of selective PDE10 inhibitors |
| IL149106A0 (en) | 2001-04-20 | 2002-11-10 | Pfizer Prod Inc | Therapeutic use of selective pde10 inhibitors |
| FR2824065A1 (fr) | 2001-04-26 | 2002-10-31 | Neuro3D | Composes inhibiteurs des phosphodiesterases des nucleotides cycliques, preparation et utilisations |
| EP1556055B1 (fr) | 2002-10-30 | 2008-10-29 | Via Pharmaceuticals, Inc. | Inhibiteurs des phosphodiesterases des nucleotides cycliques, ayant une structure benzodiazepinique, et leur utilisation en therapie |
| BRPI0411897A (pt) | 2003-06-30 | 2006-08-29 | Altana Pharma Ag | pirroldihidroisoquinolinas como inibidores de pde10 |
| ES2331519T3 (es) | 2003-06-30 | 2010-01-07 | Nycomed Gmbh | Derivados de pirrolo-dihidroisoquinolina como inhibidores de pde10. |
| CA2534432A1 (en) | 2003-07-31 | 2005-02-10 | Bayer Pharmaceuticals Corporation | Methods for treating diabetes and related disorders using pde10a inhibitors |
| JP2007523152A (ja) | 2004-02-18 | 2007-08-16 | ファイザー・プロダクツ・インク | キナゾリンおよびイソキノリンのテトラヒドロイソキノリニル誘導体 |
| FR2870539B1 (fr) | 2004-05-19 | 2006-08-04 | Greenpharma Sa Sa | Nouvelles methodes et medicaments |
| WO2005120514A1 (en) * | 2004-06-07 | 2005-12-22 | Pfizer Products Inc. | Phosphodiesterase 10 inhibition as treatment for obesity-related and metabolic syndrome-related conditions |
| US20060019975A1 (en) | 2004-07-23 | 2006-01-26 | Pfizer Inc | Novel piperidyl derivatives of quinazoline and isoquinoline |
| EP1802585A1 (en) | 2004-09-03 | 2007-07-04 | Memory Pharmaceuticals Corporation | 4-substituted 4,6-dialkoxy-cinnoline derivatives as phospodiesterase 10 inhibitors for the treatment of psychiatric or neurological syndroms |
| NL2000397C2 (nl) * | 2006-01-05 | 2007-10-30 | Pfizer Prod Inc | Bicyclische heteroarylverbindingen als PDE10 inhibitoren. |
| US20080090834A1 (en) * | 2006-07-06 | 2008-04-17 | Pfizer Inc | Selective azole pde10a inhibitor compounds |
| CN101495476A (zh) * | 2006-07-10 | 2009-07-29 | H.隆德贝克有限公司 | 6,7-二烷氧基喹唑啉、6,7-二烷氧基酞嗪和6,7-二烷氧基异喹啉的(3-芳基-哌嗪-1-基)、(2-芳基-吗啉-4-基)和(2-芳基-硫代吗啉-4-基)衍生物 |
| EP2173728A2 (en) | 2007-07-17 | 2010-04-14 | Amgen Inc. | Heterocyclic modulators of pkb |
| GB0800411D0 (en) | 2008-01-10 | 2008-02-20 | Glaxo Group Ltd | Novel compounds |
| TWI487705B (zh) | 2009-12-17 | 2015-06-11 | Lundbeck & Co As H | 作為ｐｄｅ１０ａ酵素抑制劑之雜芳香族芳基三唑衍生物 |
| TWI481607B (zh) | 2009-12-17 | 2015-04-21 | Lundbeck & Co As H | 作為ｐｄｅ１０ａ酵素抑制劑的２－芳基咪唑衍生物 |
| TWI485151B (zh) | 2009-12-17 | 2015-05-21 | Lundbeck & Co As H | 作為ｐｄｅ１０ａ酵素抑制劑之雜芳香族苯基咪唑衍生物 |
| US8969349B2 (en) * | 2010-05-26 | 2015-03-03 | Sunovion Pharmaceuticals Inc. | Substituted quinoxalines and quinoxalinones as PDE-10 inhibitors |
-
2010
- 2010-12-13 TW TW099143441A patent/TWI487705B/zh not_active IP Right Cessation
- 2010-12-15 CN CN201080064069.0A patent/CN102753550B/zh not_active Expired - Fee Related
- 2010-12-15 JP JP2012543477A patent/JP6035149B2/ja not_active Expired - Fee Related
- 2010-12-15 SI SI201030474T patent/SI2513106T1/sl unknown
- 2010-12-15 CA CA2783728A patent/CA2783728C/en not_active Expired - Fee Related
- 2010-12-15 NZ NZ600365A patent/NZ600365A/xx not_active IP Right Cessation
- 2010-12-15 PT PT107979916T patent/PT2513106E/pt unknown
- 2010-12-15 MY MYPI2012002595A patent/MY156520A/en unknown
- 2010-12-15 RS RS20130588A patent/RS53101B/en unknown
- 2010-12-15 KR KR1020127015379A patent/KR101779629B1/ko active IP Right Grant
- 2010-12-15 UA UAA201207980A patent/UA107950C2/uk unknown
- 2010-12-15 EP EP10797991.6A patent/EP2513106B1/en active Active
- 2010-12-15 MX MX2012006715A patent/MX2012006715A/es active IP Right Grant
- 2010-12-15 EA EA201290517A patent/EA021606B1/ru not_active IP Right Cessation
- 2010-12-15 SG SG2012043493A patent/SG181672A1/en unknown
- 2010-12-15 PL PL10797991T patent/PL2513106T3/pl unknown
- 2010-12-15 AU AU2010333438A patent/AU2010333438B2/en not_active Ceased
- 2010-12-15 DK DK10797991.6T patent/DK2513106T3/da active
- 2010-12-15 US US13/515,351 patent/US8501795B2/en not_active Expired - Fee Related
- 2010-12-15 MA MA35064A patent/MA33923B1/fr unknown
- 2010-12-15 ES ES10797991.6T patent/ES2442179T3/es active Active
- 2010-12-15 BR BR112012014486A patent/BR112012014486A2/pt not_active Application Discontinuation
- 2010-12-15 WO PCT/DK2010/050344 patent/WO2011072697A1/en active Application Filing
- 2010-12-15 GE GEAP201012784A patent/GEP20146201B/en unknown
- 2010-12-16 AR ARP100104669A patent/AR079496A1/es unknown
-
2012
- 2012-05-31 TN TNP2012000278A patent/TN2012000278A1/en unknown
- 2012-06-12 CR CR20120318A patent/CR20120318A/es unknown
- 2012-06-12 IL IL220328A patent/IL220328A/en not_active IP Right Cessation
- 2012-06-13 GT GT201200193A patent/GT201200193A/es unknown
- 2012-06-15 CO CO12101114A patent/CO6602117A2/es active IP Right Grant
- 2012-06-15 DO DO2012000169A patent/DOP2012000169A/es unknown
- 2012-06-15 ZA ZA2012/04420A patent/ZA201204420B/en unknown
-
2013
- 2013-04-23 HK HK13104921.1A patent/HK1177745A1/xx not_active IP Right Cessation
- 2013-06-20 US US13/922,371 patent/US8785653B2/en not_active Expired - Fee Related
- 2013-12-19 HR HRP20131210AT patent/HRP20131210T1/hr unknown
-
2014
- 2014-01-07 CY CY20141100012T patent/CY1116361T1/el unknown
- 2014-01-22 SM SM201400009T patent/SMT201400009B/xx unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO6602117A2 (es) | Derivados de aril triazol heteroaromáticos como inhibidores de enzima pde10a | |
| CO6612246A2 (es) | Derivados de 2-arilimidazol como inhibidores de enzima pde10a | |
| CO6321263A2 (es) | Nuevos derivados de fenilimidazol como inhibidores de la enzima pde10a | |
| DOP2012000165A (es) | Derivados de fenilimidazol heteroaromaticos como inhibidores de enzima pde10a | |
| IN2015DN02829A (es) | ||
| UA112065C2 (uk) | Похідні імідазолу як інгібітори ферменту pde10a | |
| UA102693C2 (ru) | Производные фенилимидазола как ингибиторы фермента pde10a | |
| ECSP14015609A (es) | Inhibidores de pde9 con estructura básica de imidazotriazinona | |
| CY1116689T1 (el) | Παραγωγα ιμιδαζολης ως αναστολεις του ενζυμου pde10a | |
| MX336915B (es) | Derivados de imidazol como inhibidores de la enzima pde10a. | |
| TN2013000200A1 (en) | Imidazole derivatives as pde 10a enzyme inhibitors |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Application granted |